Clinical Study on the Prevention and Treatment of Negative Effect after mFOLFOX6 Chemotherapy Protocol using a Combination of Xiangsha Liujunzi Paste and Ondansetron
NING Zhi1, ZHOU Dai2, DAI Xingjun1, WANG Dan1, WU Minghui1, PENG Yue2, LI Cuiying2
1. Liuyang Hospital of Traditional Chinese Medicine; 2. Changsha Hospital for Maternal & Child Health Care Affiliated to Hunan Normal University, changsha 410007, Hunan, CHINA
Abstract:Objective This study was designed to evaluate the clinical efficacy and toxic side effect of Xiangsha Liujunzi paste applied to the Shenque acupoint in combination with Ondansetron in preventing and treating nausea, vomiting, and appetite loss caused by the mFOLFOX6 chemotherapy regimen. The goal of this study was to provide scientific evidence for the integration of traditional Chinese and Western medicine in treating vomiting induced by gastric cancer chemotherapy. Methods A prospective randomized controlled trial design was employed in this study. Sixty patients who underwent radical surgery for gastric cancer with the mFOLFOX6 chemotherapy regimen were selected as subjects and randomly assigned to the control group and the treatment group. The control group received Ondansetron (8mg Q12h intravenously) on days 1, 2, and 3 of chemotherapy, while the treatment group underwent additional Shenque acupoint application treatment daily from day 1 to day 7 of chemotherapy, lasting 24 hours. Observation indicators included the incidence of nausea, acute vomiting, appetite loss during the first three days of two chemotherapy cycles, delayed vomiting on day four of chemotherapy, and Karnofsky performance scores before and after two cycles. Results The treatment group showed a higher incidence of mild (grade 0-I) nausea on days 1, 2, and 3 after the first and second cycles of chemotherapy compared to the control group, with a statistically significant difference. The effectiveness of acute vomiting treatment was also significantly higher in the treatment group. In terms of the delayed vomiting, the incidence was significantly lower in the treatment group, with a statistically significant difference. Additionally, the treatment group demonstrated a higher effectiveness in treating appetite loss compared to the control group, with a statistically significant difference. Regarding Karnofsky performance scores, both groups experienced declines, but the difference before and after chemotherapy in the treatment group was not significant, whereas it was significant in the control group; the difference between the two groups after treatment was also significant. Conclusion The combination of Xiangsha Liujunzi paste application and Ondansetron can effectively prevent and treat negative symptoms of nausea, vomiting, and appetite loss induced by the mFOLFOX6 chemotherapy regimen, and it also improves the quality of life for patients with gastric cancer. These findings provide new insights and strategies for integrating traditional Chinese and Western medicine in treating chemotherapy-related side effect.
宁智, 周戴, 戴新军, 王丹, 伍明辉, 彭越, 李翠英. 香砂六君子贴敷联合昂丹司琼在预防和治疗mFOLFOX6方案化疗后不良反应的临床研究[J]. 湖南师范大学学报(医学版), 2024, 21(4): 145-149.
NING Zhi, ZHOU Dai, DAI Xingjun, WANG Dan, WU Minghui, PENG Yue, LI Cuiying. Clinical Study on the Prevention and Treatment of Negative Effect after mFOLFOX6 Chemotherapy Protocol using a Combination of Xiangsha Liujunzi Paste and Ondansetron. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(4): 145-149.